关于未来阿尔茨海默病治疗的偏好通过使用值技术在线调查引起
S Roldan Munoz1, S T de Vries, G Lankester
1Sonia Roldan Munoz, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology. Hanzeplein 1, 9713 GZ Groningen; Building 50, entrance 45, 1st floor, Room 50.1.C.003. Department zip code AP50, mailbox 30.001. 9700 RB Groningen, s.roldan.munoz@umcg.nl.
The journal of prevention of Alzheimer's disease
|October 24, 2023
概括
人们接受阿尔茨海默病 (AD) 治疗的不同风险. 个体特征和对药物的信仰显著影响这些权衡,影响不同患者群体的治疗决策.
科学领域:
- 神经科学是一个神经科学.
- 医学伦理 医学伦理
- 卫生经济学 卫生经济学
背景情况:
- 阿尔茨海默病 (AD) 的新兴治疗方法旨在减缓进展.
- 对于寻求疾病延迟的患者,关于可接受的风险水平的数据有限.
研究的目的:
- 量化患者愿意与假设的AD治疗风险进行交易的好处.
- 评估个人特征和医学信仰如何影响这些风险-收益权衡.
主要方法:
- 对英国成年人 (n=3658) 进行了一项在线调查.
- 参与者表示对2年AD延迟中度/严重不良事件的最大可接受风险 (MAR).
- 日志正常生存模型分析了MAR和影响因素.
主要成果:
- 适度不良事件的中位数MAR为25.4%,严重事件的中位数为12.1%.
- 可接受的风险因年龄,性别,教育,生活状况和医学信仰而有很大差异.
- 护理人员身份或个人记忆问题没有影响MARs.
结论:
- 对于阿尔茨海默氏症治疗的患者风险和益处的权衡是高度个性化的.
- 承认这种异质性对于公平的药品决策和满足不同患者需求至关重要.
相关概念视频
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500